Addendum to Recce Signs Middle East Licensing Term Sheet
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. has released an addendum regarding a licensing term sheet with a Middle Eastern pharmaceutical company for an exclusive arrangement. The company confirms that the identity of the counterparty is not expected to materially affect the value of its securities. The announcement includes all relevant information for assessing the contract's impact on the company's securities. Recce Pharmaceuticals is developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Recce Signs Middle East Licensing Term Sheet
- Brazil Patent Granted for RECCE Anti-Infectives
- RCE Investor Webinar Presentation Deck
- Appendix 4D and Interim Financial Report
- Recce Enters Second U.S. Department of Defense R&D Agreement
Later from Recce Pharmaceuticals
- HREC Approval Accelerates Global Phase 3 DFI Strategy
- Placement & SPP to raise $8 million
- AUD $3.7M Income Tax Refund Received
- Vietnamese Patent Granted for RECCE Anti-Infectives
- HREC Approves Comparator Study for Pivotal Phase 3 DFI
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals